179 related articles for article (PubMed ID: 26115798)
1. The place of PD-1 inhibitors in melanoma management.
Bowyer S; Lorigan P
Lancet Oncol; 2015 Aug; 16(8):873-4. PubMed ID: 26115798
[No Abstract] [Full Text] [Related]
2. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
Fløe LE; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
4. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
5. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
6. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy: pembrolizumab-is the writing on the wall for cancer?
Hutchinson L
Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092
[No Abstract] [Full Text] [Related]
8. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
9. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
Robert C; Mateus C
Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705
[TBL] [Abstract][Full Text] [Related]
10. PD-1 Blockade in Melanoma: A Promising Start, but a Long Way to Go.
Bhatia S; Thompson JA
JAMA; 2016 Apr; 315(15):1573-5. PubMed ID: 27092829
[No Abstract] [Full Text] [Related]
11. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
12. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
13. Combining immune checkpoint inhibitors for advanced melanoma: the key to optimizing treatment outcomes?
Freeston S
J Comp Eff Res; 2016 Jul; 5(4):329-33. PubMed ID: 27331424
[No Abstract] [Full Text] [Related]
14. Pembrolizumab for melanoma- safety profile and future trends.
Daud A; Nandoskar P
Expert Opin Drug Saf; 2016 Jun; 15(6):727-9. PubMed ID: 27056241
[No Abstract] [Full Text] [Related]
15. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
16. Setting the bar for adjuvant treatment of melanoma.
Sondak VK; Gibney GT
Lancet Oncol; 2014 May; 15(6):547-8. PubMed ID: 24745697
[No Abstract] [Full Text] [Related]
17. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
18. From ASCO-targeted therapies: Anti-PD-1 approaches--important steps forward in metastatic melanoma.
Razzak M
Nat Rev Clin Oncol; 2013 Jul; 10(7):365. PubMed ID: 23752732
[No Abstract] [Full Text] [Related]
19. Combined immunotherapy improves survival in metastatic melanoma.
Mayor S
BMJ; 2015 Jun; 350():h2993. PubMed ID: 26036979
[No Abstract] [Full Text] [Related]
20. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
[Next] [New Search]
